Payment overview · 2025
General Payments
$616.77
16 reported records · 6 companies
Healthcare provider profile · identity verified
Bruce Alan Barker, DO
Allopathic & Osteopathic Physicians|Family Medicine · BAY CITY, TX · NPI 1548248461
Verified facts
What the public records show
CMS Open Payments records show Bruce Alan Barker, DO received $616.77 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.80 | 29.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.28 | 26.3% | 8 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $121.84 | 19.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.66 | 12.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $44.38 | 7.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.81 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.77 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $162.28 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.02 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $131.24 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.66 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $44.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.78 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 570 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 503 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 133 |
| Furosemide | Furosemide | 358 | 86 |
| Lisinopril | Lisinopril | 334 | 97 |
| Gabapentin | Gabapentin | 326 | 105 |
| Metformin Hcl | Metformin Hcl | 324 | 119 |
| Losartan Potassium | Losartan Potassium | 294 | 87 |
| Potassium Chloride | Potassium Chloride | 238 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 63 |
| Eliquis | Apixaban | 219 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 63 |
| Sertraline Hcl | Sertraline Hcl | 215 | 50 |
| Montelukast Sodium | Montelukast Sodium | 209 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 57 |
| Trazodone Hcl | Trazodone Hcl | 190 | 45 |
| Donepezil Hcl | Donepezil Hcl | 178 | 38 |
| Carvedilol | Carvedilol | 169 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 30 |
| Allopurinol | Allopurinol | 157 | 38 |
| Divalproex Sodium | Divalproex Sodium | 139 | 28 |
| Farxiga | Dapagliflozin Propanediol | 137 | 28 |
| Memantine Hcl | Memantine Hcl | 132 | 28 |
| Omeprazole | Omeprazole | 128 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 42 |
| Mirtazapine | Mirtazapine | 120 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 39 |
| Simvastatin | Simvastatin | 113 | 35 |
| Famotidine | Famotidine | 100 | 23 |
| Fenofibrate | Fenofibrate | 96 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 66 |
| Buspirone Hcl | Buspirone Hcl | 87 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 30 |
| Meloxicam | Meloxicam | 83 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 22 |
| Nifedipine Er | Nifedipine | 82 | 22 |
| Tramadol Hcl | Tramadol Hcl | 82 | 25 |
| Levetiracetam | Levetiracetam | 80 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 29 |
| Lorazepam | Lorazepam | 79 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 20 |
| Methylprednisolone | Methylprednisolone | 78 | 66 |
| Xarelto | Rivaroxaban | 78 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 18 |
| Pregabalin | Pregabalin | 68 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 20 |
| Digoxin | Digoxin | 63 | 14 |
| Myrbetriq | Mirabegron | 63 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 16 |
| Januvia | Sitagliptin Phosphate | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 14 |
| Finasteride | Finasteride | 56 | 13 |
| Methocarbamol | Methocarbamol | 55 | 32 |
| Latanoprost | Latanoprost | 53 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 40 |
| Albuterol Sulfate | Albuterol Sulfate | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 17 |
| Ozempic | Semaglutide | 51 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Glipizide | Glipizide | 47 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 17 |
| Atenolol | Atenolol | 45 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 12 |
| Spironolactone | Spironolactone | 43 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 18 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 12 |
| Gemtesa | Vibegron | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Methadone Hcl | Methadone Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 34 | 11 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Humulin R | Insulin Regular, Human | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Sulfasalazine Dr | Sulfasalazine | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.77 · 16 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, BREZTRI, FARXIGA, INGREZZA, OTEZLA, Ozempic, REPATHA, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error